Distribution of bleeding events of patients on triple therapy by bleeding site.

<p>Distribution of bleeding events of patients on triple therapy by bleeding site.</p

Screening algorithm of patients on triple therapy after stent implantation.

<p>A total of 24892 patients were treated within 2000 and 2012. A computerized search returned 1244 hits of which 213 were actually discharged on triple therapy. Complete data is available on 138 patients.</p

Number of patients discharged on triple therapy by year.

<p>Number of patients discharged on triple therapy by year.</p

Distribution of proton pump inhibitor usage of all patients and of patients with bleeding events.

<p>PPI: proton pump inhibitor.</p

Distribution of the CHA₂DS₂-VASc and the HAS-BLED Score of all patients on triple therapy.

<p>Distribution of the CHA₂DS₂-VASc and the HAS-BLED Score of all patients on triple therapy.</p

Engineering Asymmetric Lipid Vesicles: Accurate and Convenient Control of the Outer Leaflet Lipid Composition

The asymmetric distribution of lipids between the two bilayer leaflets represents a typical feature of biological membranes. The loss of this asymmetry, for example the exposure of negatively charged lipids on the extracellular membrane leaflet of mammalian cells, is involved in apoptosis and occurs in tumor cells. Thus, the controlled production of asymmetric liposomes helps to better understand such crucial cellular processes. Here, we present an approach that allows us to design asymmetric model-membrane experiments on a rational basis and predict the fraction of exchanged lipid. In addition, we developed a label-free and nondestructive assay to quantify the asymmetric uptake of negatively charged lipids in terms of the zeta potential. This significantly enhances the applicability, impact, and predictive power of model membranes